BUZZ-Nurix Therapeutics climbs after blood cancer drug trial data

Reuters12-08 22:07

BUZZ-<a href="https://laohu8.com/S/NRIX">Nurix Therapeutics</a> climbs after blood cancer drug trial data

** Shares of drug developer Nurix Therapeutics NRIX.O jump 19.6% to $21.63 premarket

** NRIX said 75% of patients demonstrated objective response rate in early-stage trial for blood cancer drug Bexobrutideg (NX-5948), with mostly mild side effects

** Drug is aimed at degrading BTK, a protein that drives the disease

** NRIX set to open at its highest after a year if current gains hold

** Stock down nearly 4% YTD, up to last close

(Reporting by Utkarsh Tushar Hathi)

((utkarshtushar.hathi@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589451356?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589451356","market":"us","top_or_hot":-1,"title":"BUZZ-Nurix Therapeutics climbs after blood cancer drug trial data","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> climbs after blood cancer drug trial data</title></head><body><p>** Shares of drug developer Nurix <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>NRIX.O</span> jump 19.6% to $21.63 premarket</p><p>** NRIX said 75% of patients demonstrated objective response rate in early-stage trial for blood cancer drug Bexobrutideg (NX-5948), with mostly mild side effects </p><p>** Drug is aimed at degrading BTK, a protein that drives the disease</p><p>** NRIX set to open at its highest after a year if current gains hold</p><p>** Stock down nearly 4% YTD, up to last close</p><p>(Reporting by Utkarsh Tushar Hathi)</p><p>((utkarshtushar.hathi@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Nurix Therapeutics climbs after blood cancer drug trial data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Nurix Therapeutics climbs after blood cancer drug trial data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> climbs after blood cancer drug trial data</title></head><body><p>** Shares of drug developer Nurix <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>NRIX.O</span> jump 19.6% to $21.63 premarket</p><p>** NRIX said 75% of patients demonstrated objective response rate in early-stage trial for blood cancer drug Bexobrutideg (NX-5948), with mostly mild side effects </p><p>** Drug is aimed at degrading BTK, a protein that drives the disease</p><p>** NRIX set to open at its highest after a year if current gains hold</p><p>** Stock down nearly 4% YTD, up to last close</p><p>(Reporting by Utkarsh Tushar Hathi)</p><p>((utkarshtushar.hathi@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRIX","symbol_name":"Nurix Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL6N3XE0RZ:1","article_id":"2589451356","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589451356","pubTimestamp":1765202850,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Nurix Therapeutics climbs after blood cancer drug trial data** Shares of drug developer Nurix Therapeutics NRIX.O jump 19.6% to $21.63 premarket** NRIX said 75% of patients demonstrated objective","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRIX":"Nurix Therapeutics","BK4139":"生物科技"},"translate_title":"BUZZ-Nurix Therapeutics在血癌药物试验数据公布后股价攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":0.9},"content_text":"BUZZ-Nurix Therapeutics climbs after blood cancer drug trial data** Shares of drug developer Nurix Therapeutics NRIX.O jump 19.6% to $21.63 premarket** NRIX said 75% of patients demonstrated objective response rate in early-stage trial for blood cancer drug Bexobrutideg (NX-5948), with mostly mild side effects ** Drug is aimed at degrading BTK, a protein that drives the disease** NRIX set to open at its highest after a year if current gains hold** Stock down nearly 4% YTD, up to last close(Reporting by Utkarsh Tushar Hathi)((utkarshtushar.hathi@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589451356","isCrawlerRequest":true}